Abstract
A paralog synthetic-lethal interaction between VRK1 and VRK2 sensitizes VRK2-methylated glioblastoma to perturbation of VRK1 kinase activity, supporting VRK1 as a drug discovery target in this disease.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have